Literature DB >> 17953112

Imported Chikungunya Infection, Italy.

Anna Beltrame, Andrea Angheben, Zeno Bisoffi, Geraldo Monteiro, Stefania Marocco, Guido Calleri, Filippo Lipani, Federico Gobbi, Francesca Canta, Francesco Castelli, Maurizio Gulletta, Sara Bigoni, Veronica Del Punta, Tiziana Iacovazzi, Roberto Romi, Loredana Nicoletti, Maria Grazia Ciufolini, Giada Rorato, Camilla Negri, Pierluigi Viale.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17953112      PMCID: PMC2828087          DOI: 10.3201/eid1308.070161

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Chikungunya virus (CHIKV) infection is a self-limiting illness characterized by fever, headache, weakness, rash, and arthralgia. Some patients have prolonged weakness or arthralgia lasting several months. In 2006, several Indian Ocean states and India had an outbreak of CHIKV infection (,). During the epidemic’s peak, some European and American travelers returning from these areas were infected (–). Because the foci of Aedes albopictus, 1 of the 2 main vectors of CHIKV, are now in Italy and many travelers visit CHIKV-epidemic areas, surveillance for imported cases is mandatory in Italy (). From July to September 2006, a total of 17 confirmed cases of CHIKV infection were observed in travelers at 5 Gruppo di Interesse e Studio delle Patologie di Importazione (GISPI) centers (Italian network of Institutes of Infectious and Tropical Diseases). Serologic diagnosis was performed with a hemagglutination-inhibition test and confirmed by a plaque-reduction neutralization test (). Demographic and epidemiologic characteristics of these patients are reported in the Table.
Table

Demographic and epidemiologic data on 17 travelers with chikungunya infection diagnosed in 2006, Italy

Patient no.SexAge, yReason for travelCountry of originDate of return (length of stay, d)Date of first medical assessment after return (delay, d)Last date of fever (length of fever, d)Fever on date of return?
1*M32BusinessRéunionFeb 23 (93)Feb 25 (2)Feb 26 (4)Yes
2†F39TourismMauritiusFeb 28 (10)Feb 28 (0)Feb 28 (4)Yes
3‡M46TourismMauritiusMar 7 (10)Mar 7 (0)Mar 6 (5)No
4‡M32TourismMadagascarMar 7 (15)Mar 8 (1)Mar 4 (4)No
M49TourismMauritiusMar 08 (16)Mar 15 (7)Mar 4 (5)No
6‡M66TourismMadagascarMar 24 (15)Mar 24 (0)Mar 27 (5)Yes
M36TourismMauritiusApr 4 (15)Apr 5 (1)Apr 1 (6)No
8*F43ResidentMadagascarApr 10 (–)Apr 11 (1)Mar 2 (6)No
9‡F46TourismRéunionJan 30 (16)Apr 13 (73)NA (2)
10¶F44Visit relativesMauritiusApr 17 (33)Apr 19 (2)Apr 7 (12)No
11‡F36TourismMauritiusApr 30 (11)May 3 (3)May 3 (3)Yes
12‡M31TourismRéunionApr 21 (30)May 4 (13)Apr 5 (6)No
13‡M44Visit relativesCameroonMay 3 (24)May 22 (19)May 7 (6)Yes
14*M35TourismSeychellesMay 31 (9)Jun 1 (1)Jun 1 (2)Yes
15*M38TourismMauritiusMay 10 (11)Jun 12 (2)May 7 (4)No
16‡F58Missionary workCentral African RepublicJun 24 (14 y)Jul 10 (16)Apr 26 (12)No
17*F57BusinessIndiaSep 8 (31)Sep 9 (1)Sep 10 (4)Yes

*GISPI (Gruppo di Interesse e Studio delle Patologie di Importazione) centers: Torino.
†GISPI center: Udine.
‡GISPI center: Negrar. NA, not available.
§GISPI center: Brescia.
¶GISPI center: Triggiano.

*GISPI (Gruppo di Interesse e Studio delle Patologie di Importazione) centers: Torino.
†GISPI center: Udine.
‡GISPI center: Negrar. NA, not available.
§GISPI center: Brescia.
¶GISPI center: Triggiano. Cases were distributed throughout the year with a peak from March to May 2006 (n = 10). Nine patients (53%) were men. Median age was 43 years (range 31–66 years). Several reasons for travel were reported: tourism (64.6%), visits to relatives or friends (11.8%), business (11.8%), and missionary work (5.9%). One patient was a resident in the disease-epidemic area. The median exposure time in the CHIKV-endemic area for the 15 travelers was 15 days (range 9–93 days) (missionary and resident patients were excluded). The median delay before being seen at a clinic after return was 2 days (range 0–73 days). Only 7 patients (41.2%) were hospitalized. The remainder were outpatients. All patients had fever; arthralgia (88.2%, n = 15), weakness (70.6%, n = 12), headache (11.8%, n = 2), diarrhea (11.8%, n = 2), and gum bleeding and epistaxis (5.9%, n = 1) were other reported symptoms. The median duration of fever was 5 days (range 2–12 days). Only 7 of 16 patients (43.8%) were still febrile when first seen. Physical examination showed diffuse macular erythematous rash in 13 patients (76.5%), a similar rate to that reported among French travelers (). Hepatomegaly was found in 2 patients (11.8%), splenomegaly in 2 (11.8%), and peripheral lymphadenopathy in 2 (11.8%). Twelve acute-phase patients were admitted to the hospital for blood testing within 3 days of the initial examination. In contrast with results of other studies, leukopenia and thrombocytopenia were uncommon in our study. Leukopenia (leukocyte count <4,000/μL) was present in 4 patients (33.3%) and thrombocytopenia (platelet count <150,000/μL) in 1 patient (8.3%). This finding may help distinguish CHIKV infection from dengue fever (). Anemia (hemoglobin level <12 g/dL) was found in only 1 patient (8.3%). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) determination were available for 12 patients. ALT and AST levels were elevated (>40 IU/L) in 5 (41.7%) and 2 (16.7%) patients, respectively. Seven (46.7%) of 15 patients fully recovered within 1 month; 8 patients (53.3%) reported persistent arthralgia. Because the GISPI network provides regional coverage only, the number of imported CHIKV cases in all of Italy in 2006 was likely higher. Moreover, most patients probably did not seek medical care, and when they did, physicians may have failed to recognize the disease because of lack of familiarity with it or limited diagnostic facilities. Differential diagnosis with other arthropodborne viruses of the Alphavirus genus (Ross River, Barmah Forest, o’nyong nyong, Sindbis, and Mayaro viruses) is difficult, but these are comparatively rare. In contrast, dengue and CHIKV epidemics may overlap, and potential patients should be screened for both. The potential risk for introduction and establishment of CHIKV reservoirs in areas with mosquito vectors was discussed in March 2006 by a multidisciplinary European expert panel (). In Italy, A. albopictus was first recorded in 1990; it has since quickly spread across the country. Scattered foci are now reported in almost all regions, mainly along the coastal plains, from the sea to the inlands, up to an altitude of ≈500–600 m (). The ability of A. albopictus to colonize new areas and its adaptability to the mild Italian climate allow vector populations to be active throughout the year (). The patient is thought to be viremic for only 6–7 days (shortly before and during the febrile period) (). We were unable to directly assess viremia levels; however, almost half the patients were still febrile on return to Italy, which suggests a potential risk. Although the same mosquito is a potential vector of dengue, no autochthonous case has been reported as yet, despite annual reports of many imported dengue cases in Italy. On the other hand, the clinical manifestations of both conditions are nonspecific, and a hypothetical autochthonous case would most likely go undiagnosed unless a targeted surveillance system were established. Prompt reporting of imported CHIKV infections is essential for monitoring of potential risk. The possibility of introducing CHIKV into Italy cannot be ruled out on the basis of current evidence.
  9 in total

1.  Chikungunya risk assessment for Europe: recommendations for action.

Authors:  E Depoortere; D Coulombier
Journal:  Euro Surveill       Date:  2006-05-11

2.  Chikungunya: an epidemic in real time.

Authors:  Patrick Bodenmann; Blaise Genton
Journal:  Lancet       Date:  2006-07-15       Impact factor: 79.321

3.  Failure to control mosquitoes has led to two fever epidemics in India.

Authors:  Ganapati Mudur
Journal:  BMJ       Date:  2006-10-14

4.  [Aedes albopictus in Italy: an underestimated health problem].

Authors:  R Romi
Journal:  Ann Ist Super Sanita       Date:  2001       Impact factor: 1.663

5.  Cold acclimation and overwintering of female Aedes albopictus in Roma.

Authors:  Roberto Romi; Francesco Severini; Luciano Toma
Journal:  J Am Mosq Control Assoc       Date:  2006-03       Impact factor: 0.917

6.  Chikungunya fever diagnosed among international travelers--United States, 2005-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-09-29       Impact factor: 17.586

Review 7.  Sandfly fever viruses in Italy.

Authors:  L Nicoletti; M G Ciufolini; P Verani
Journal:  Arch Virol Suppl       Date:  1996

8.  Chikungunya infection in travelers.

Authors:  Patrick Hochedez; Stephane Jaureguiberry; Monique Debruyne; Philippe Bossi; Pierre Hausfater; Gilles Brucker; Francois Bricaire; Eric Caumes
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

9.  Novel chikungunya virus variant in travelers returning from Indian Ocean islands.

Authors:  Philippe Parola; Xavier de Lamballerie; Jacques Jourdan; Clarisse Rovery; Véronique Vaillant; Philippe Minodier; Philippe Brouqui; Antoine Flahault; Didier Raoult; Rémi N Charrel
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

  9 in total
  45 in total

Review 1.  The arrival, establishment and spread of exotic diseases: patterns and predictions.

Authors:  Sarah E Randolph; David J Rogers
Journal:  Nat Rev Microbiol       Date:  2010-04-07       Impact factor: 60.633

2.  Chikungunya in Italy.

Authors:  Jo Lines
Journal:  BMJ       Date:  2007-09-18

Review 3.  Incubation periods of mosquito-borne viral infections: a systematic review.

Authors:  Kara E Rudolph; Justin Lessler; Rachael M Moloney; Brittany Kmush; Derek A T Cummings
Journal:  Am J Trop Med Hyg       Date:  2014-03-17       Impact factor: 2.345

4.  Suppressing Aedes albopictus, an emerging vector of dengue and chikungunya viruses, by a novel combination of a monomolecular film and an insect-growth regulator.

Authors:  Mark Nelder; Banugopan Kesavaraju; Ary Farajollahi; Sean Healy; Isik Unlu; Taryn Crepeau; Ashok Ragavendran; Dina Fonseca; Randy Gaugler
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

5.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

6.  HLA class I restriction as a possible driving force for Chikungunya evolution.

Authors:  Joo Chuan Tong; Diane Simarmata; Raymond T P Lin; Laurent Rénia; Lisa F P Ng
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

7.  piggybac- and PhiC31-mediated genetic transformation of the Asian tiger mosquito, Aedes albopictus (Skuse).

Authors:  Geneviève M C Labbé; Derric D Nimmo; Luke Alphey
Journal:  PLoS Negl Trop Dis       Date:  2010-08-17

8.  Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.

Authors:  Angela Chow; Zhisheng Her; Edward K S Ong; Jin-miao Chen; Frederico Dimatatac; Dyan J C Kwek; Timothy Barkham; Henry Yang; Laurent Rénia; Yee-Sin Leo; Lisa F P Ng
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

9.  Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice.

Authors:  Kristin M Long; Alan C Whitmore; Martin T Ferris; Gregory D Sempowski; Charles McGee; Bianca Trollinger; Bronwyn Gunn; Mark T Heise
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Characterisation of a chikungunya virus from a German patient returning from Mauritius and development of a serological test.

Authors:  Stefan Kowalzik; Nghia Vu Xuan; Benedikt Weissbrich; Barbara Scheiner; Tanja Schied; Christian Drosten; Andreas Müller; August Stich; Axel Rethwilm; Jochen Bodem
Journal:  Med Microbiol Immunol       Date:  2008-03-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.